Farmington-based bioscience startup CaroGen reports its immunotherapy vaccine that targets chronic Hepatitis B has been recommended for $6.8 million in federal funding by the U.S. Department of Defense.
CaroGen, which has been developing immunotherapies for cancer and infectious diseases at its lab space inside UConn’s Technology Incubation Program facility in Farmington, said that the U.S. Department of Defense Office of the Congressionally Directed Medical Research Programs recommended the funding award, which would enable further development of the company’s vaccine for the treatment of chronic hepatitis B.